CD4 and type 1 diabetes mellitus: Similarly, in the adoptive transfer model of T1D, a competitive inhibitor of the glycolytic rate-limiting enzyme of CD4+ T cells reduced T cell responses to β cell antigen in vitro, thus reducing the immunopathological parameters associated with disease onset as 57% of animals remaining euglycemic at the end of the study period (22).